You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma

 

Online download statistics by month:

Online download statistics by month: October 2020 to August 2024

AbstractFullPdf
Oct 202010210241
Nov 2020262258163
Dec 202012612652
Jan 202112912965
Feb 202112412449
Mar 202116916946
Apr 202114014051
May 202110010034
Jun 202111911857
Jul 2021909053
Aug 2021898938
Sep 2021898952
Oct 2021898965
Nov 2021747451
Dec 2021626438
Jan 2022515219
Feb 2022363830
Mar 202211511829
Apr 2022939643
May 2022999931
Jun 2022858628
Jul 2022676823
Aug 2022818123
Sep 2022586024
Oct 2022747645
Nov 2022575721
Dec 2022626222
Jan 2023666720
Feb 202312312335
Mar 2023879544
Apr 2023606219
May 2023697022
Jun 2023606014
Jul 2023585820
Aug 2023535317
Sep 2023454514
Oct 2023666621
Nov 2023707023
Dec 2023868628
Jan 2024333424
Feb 2024505015
Mar 20249292120
Apr 2024646544
May 202426326335
Jun 2024606020
Jul 202438738726
Aug 2024464523
Total448045051777